Summary Information:
Poseida Therapeutics Inc. Common Stock
NASDAQ:PSTX


email
admin@troach.net
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


Poseida Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: PSTX
SEC CIK: 0001661460
Phone: 858-779-3100
9390 TOWNE CENTRE DRIVE
SUITE 200
SAN DIEGO CA 92121
CEO: Eric Ostertag
Price when page updated: 2.66 Date: 2023-12-01
Company Website:
poseida.com

_Description: Poseida Therapeutics is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next generation cell and gene therapeutics with the capacity to cure. Poseida has discovered and are developing a broad portfolio of product candidates in a variety of indications based on its core proprietary platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. Its core platform technologies have utility, either alone or in combination, across many cell and gene therapeutic modalities and enable Poseida Therapeutics to engineer its wholly-owned portfolio of product candidates that are designed to overcome the primary limitations of current generation cell and gene therapeutics.

IPO YEAR:
2020
Sector:
Consumer Durables
Industry:
Specialty Chemicals
ADRTSO:

MarketCap:
254361008.00
Beta:
0.771894267621914
52 Week High:
13.64
52 Week Low:
4.93
52 Week Change:
-0.39400921658986177
Short Interest:

Short Date:

Shares Outstanding:
62506279
Dividend Rate:
0
Dividend Yield:
N/A
ExDividend Date:

Latest EPS:

Latest EPS Date:
7 Nov 2022
Float:
0
return on Equity:
-119.40%
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
-$156.22
ttmEPS:
0
Revenue:
$35.373M
Gross Profit:

Cash:

Debt:

Institution Percent:
29.80%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
14.90%
Return on Assets:
-57.70%
Return on Capital:

Profit Margin:
-
Price to Sales:
9.31
Price To Book:
3.61
Short Ratio:
1.28
PE Ratio:
0
Employees:
206
1Y Guesstimate
11.945:2.0:6




__The following are links to various summary and news pages for
__Poseida Therapeutics Inc. Common Stock [ PSTX ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-12-01